SlideShare uma empresa Scribd logo
1 de 29
Baixar para ler offline
Regulatory Guidelines for
the Development of
Biologics in the Europe
JAYA PRAKASH V,
REGULATORY AFFAIRS,
218311.
CONTENTS
• Introduction
• EU Guidelines
Non clinical studies
Clinical studies
MAA
• Regulatory strategy for marketing
INTRODUCTION
• In the European Union, biologics are largely defined in
terms of their active substances and methods of
manufacture.
• EU recognize that biologics are comes under special
treatment.
• This document provides an overview of the EU
regulatory schemes, from nonclinical trials through
clinical trials to approval.
EUROPEAN UNION GUIDELINES
• Biological medicines are defined as “products, the active
substance of which is a biological substance.
• A “biological substance” in turn, is defined as “a substance
that is produced by or extracted from a biological source.
• And needs for its characterization and the determination of
its quality ,physico-chemical-biological testing, together
with the production process and its control.
Examples
• Immunologic medicines.
• Medicines derived from human blood and plasma.
• Medicines developed by means of recombinant DNA
technology.
• Hybridoma and mAb methods.
Nonclinical Studies
• The Committee for Medicinal Products for Human Use
(CHMP) has adopted ICH S6 as a guideline governing
preclinical testing of biologics.
• The CHMP adopted the addendum to this guideline, and
the addendum came into effect in Europe in 2011.
• The addendum complements, clarifies, and updates ICH
S6 and is intended to further harmonize the standards
for nonclinical studies.
General Principles
The addendum covers the following five topics:
Species selection Study design Immunogenicity
Reproductive
and
developmental
toxicity
Carcinogenicity
Species Selection
• According to the addendum the factors that sponsors
should consider are as follows:
subsequent in vitro assays making qualitative and
quantitative cross species comparisons of relative target
binding affinities.
receptor– ligand occupancy.
kinetics.
Sponsors also should assess functional activity.
• Specific instructions are provided for mAbs, for which a
short term safety study in one species and no additional
toxicity studies are recommended.
• If there are two relevant species (one rodent and one non
rodent), the sponsor should conduct short-term studies
in both.
• If the toxicologic findings from these studies are similar
for both species, long-term studies may involve one of
those species.
Study Design
• When selecting the high dose for toxicity testing , the
high dose should be the higher of -
The dose providing the maximum intended
pharmacologic effect in the preclinical species.
The dose providing an approximately 10-fold exposure
over the maximum exposure to be achieved in the clinic.
When no PD endpoint is available, the sponsor should
select the high dose based on PK data.
• Generally, repeat-dose toxicity tests should have a
duration of 6 months; studies of longer duration are not
considered valuable.
• Finally, the sponsor may need to assess subject recovery
from the medicine’s pharmacologic and toxicologic
effects.
Immunogenicity
• As noted in ICH S6,non clinical studies are not useful in
predicting potential immunogenicity of human or
humanized proteins in humans.
• The sponsor should measure antidrug antibodies
(ADAs), namely when
(1) There is evidence of altered PD activity.
(2) There are unexpected changes in exposure in the
absence of a PD marker.
(3) there is evidence of immune-mediated reactions.
• Collection of appropriate samples during the study is
recommended.
Reproductive and Developmental
Toxicity
• The addendum first provides general advice on
reproductive and developmental testing and then
discusses more specific recommendations for
Fertility studies.
Embryo–fetal development (EFD) studies.
pre-and post natal development (PPND)studies.
Studies in nonhuman primates (NHPs).
• Reproductive studies should occur in a relevant species,
but no such studies are required for products directed at
foreign targets, such as bacteria and viruses.
• Sponsors should not use NHPs in developmental testing
unless they are the only relevant species, and even then,
the sponsor can provide scientific justification to use an
alternative model.
• If no relevant species exists, the sponsor may consider
using transgenic mice.
• If the weight of the evidence suggests an adverse effect
on fertility or pregnancy, and additional studies might
not be warranted.
• When the product’s mechanism of action raises serious
developmental toxicity concerns and NHPs are the only
relevant species.
• No study is necessary. instead, the labeling should
disclose the concern, and the sponsor should avoid
administering the candidate to women of child bearing
potential
Carcinogenicity
• As noted, carcinogenicity assessments of biologics are
not always warranted, but the addendum provides advice
for use in situations when they are appropriate.
• According to the addendum, the sponsor may design a
strategy addressing potential carcinogenicity based on a
weight of evidence, including a review of relevant
information such as :
• Literature.
• Target biology and mechanisms of action.
• In vitro data .
• Clinical data.
• Data from chronic toxicity studies.
• In situations the weight of the evidence supports them,
the hazard should be addressed through product labeling
and risk management practices.
• If the weight of the evidence is unclear, the sponsor can
propose additional studies to address it.
• If this assessment instead suggests no carcinogenicity
concern, additional nonclinical testing is not
recommended.
Clinical Studies in Compliance with the
Clinical Trials Directive
• This section summarizes the requirements of the Clinical
Trials Directive.
Clinical trail authorisation
Good clinical practice and other
aspects
Study design Consultation with EMA
CLININCAL TRAILS
REQUIRMENTS
Clinical Trial Authorization
A clinical trial may commence only if :
 The anticipated therapeutic and public health benefits
outweigh risks and inconveniences to the subjects.
 The trial subjects understand the objectives and risks of
the trial and give informed, written consent to
participate.
 The trial safeguards the physical and mental integrity of
the subjects.
 Insurance covers the liability of the sponsor and
investigator.
• In general, the sponsor must take responsibility for the
following:
Trial conduct
Appointment of an appropriate investigator
selection of the institution that will conduct the trial
data collection standards etc.,
• The trial may begin only if
(1) The ethics committee has issued a favorable opinion.
(2) No competent authority has informed the applicant of
grounds for non acceptance.
Good Clinical Practices and Other aspects
for Clinical Trials
• Clinical trials of biologics must comply with Good
Clinical Practice and the ICH E6.
• Investigators must obtain freely given informed consent.
• Clinical trial information must be handled, recorded, and
stored with respect for relevant confidentiality and
privacy rules.
• Trials must comply with the ethical principles.
• Confirm that the benefits of the trial outweigh the risks,
and ensure safety to the subjects.
• CHMP has issued a guideline on quality :
An adequate description of the process and process
controls.
A description and justification of “any reprocessing
during manufacture of the drug substance”.
• For first-in-human (FIH) clinical trials, sponsors should
use product representative of the material used during
the nonclinical testing phase.
Study Design Considerations
• General guidance on study design applies to biologics as
well as small molecule medicines.
• Phase I usually involves the initial safety and pk studies.
• phase II study is a therapeutic exploratory study that
explores efficacy.
• Phase III typically involves therapeutic confirmatory
studies.
Consultation with the EMA
• A sponsor may obtain, from the EMA, scientific advice
regarding clinical trial protocols.
• Generally focus on matters such as the selection of
endpoints and comparator, the duration of treatment or
follow-up, and the design of pivotal studies.
• If the applicant decides not to follow the EMA’s advice, it
should justify this decision in its MAA.
The Marketing Authorization Application-
Contents and Approval Standard
The requirements of the EU centralized procedure are :
The approval standards for Biotechnology products are
the same as for chemically synthesized medicines.
Both types of products must be safe and effective and
have appropriate quality.
MAAs for biologics also must meet special requirements:
The applicant must thoroughly describe the
manufacturing process , facilities and equipment.
provide information on the origin and history of the
starting materials.
demonstrate that the active substance complies with
specific measures for preventing the transmission of
animal spongi form encephalopathies.
if cell banks are used, demonstrate that cell
characteristics remain unchanged at the passage level for
production (and beyond).
describe the origin, criteria, and procedures for the
collection, transportation, and storage of the starting
material if they derived from human blood and plasma
REGULATORY STRATEGIES FOR WORLDWIDE
MARKETING OF BIOLOGICAL PRODUCTS
• Acceptance of Foreign Clinical Studies in the Europe
• Europe Directive 2001/83/EC allows for clinical trials
conducted outside the European Union.
• If such trials have been designed, implemented, and
reported based on principles equivalent to those of the
Clinical Trials Directive with regard to good clinical
practice and ethical principles.
Success is never owned; it is only
rented, and the rent is due every
day!
THANK YOU

Mais conteúdo relacionado

Mais procurados

Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsLabeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsMichael Swit
 
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxCLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxFaizanShaikh204666
 
Regulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usRegulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usVinod Raj
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countriesJAYA PRAKASH VELUCHURI
 
REGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxREGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxAartiVats5
 
Post Marketing Survelliance.pptx
Post Marketing Survelliance.pptxPost Marketing Survelliance.pptx
Post Marketing Survelliance.pptxPrachiSharma575050
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japanManish kumar
 
NSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplementNSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplementAtul Bhombe
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxINVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxPrachiSharma575050
 
International Medical Device Regulators Forum
International Medical Device Regulators ForumInternational Medical Device Regulators Forum
International Medical Device Regulators ForumSanthiNori1
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letterSridhar S
 
Development and Regulatory Approval of Biologics in European Union (Investiga...
Development and Regulatory Approval of Biologics in European Union (Investiga...Development and Regulatory Approval of Biologics in European Union (Investiga...
Development and Regulatory Approval of Biologics in European Union (Investiga...VanshikaGupta948537
 
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxGLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxSanthiNori1
 
GMP for Nutraceuticals .pdf
GMP for Nutraceuticals  .pdfGMP for Nutraceuticals  .pdf
GMP for Nutraceuticals .pdfBhavikaAPatel
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
 

Mais procurados (20)

Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsLabeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
 
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxCLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
 
Regulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usRegulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in us
 
Market authorisation checklist for brics countries
Market authorisation checklist for brics countriesMarket authorisation checklist for brics countries
Market authorisation checklist for brics countries
 
Medical Device Regulations - 510(k) Process
Medical Device Regulations - 510(k) ProcessMedical Device Regulations - 510(k) Process
Medical Device Regulations - 510(k) Process
 
REGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptxREGULATORY CONSIDERATIONS IN JAPAN.pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptx
 
Post Marketing Survelliance.pptx
Post Marketing Survelliance.pptxPost Marketing Survelliance.pptx
Post Marketing Survelliance.pptx
 
STED
STEDSTED
STED
 
Drug approval process in japan
Drug approval process in japanDrug approval process in japan
Drug approval process in japan
 
NSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplementNSF certification, Standard for dietary supplement
NSF certification, Standard for dietary supplement
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptxINVESTIGATIONAL DEVICE EXEMPTIONS.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
 
International Medical Device Regulators Forum
International Medical Device Regulators ForumInternational Medical Device Regulators Forum
International Medical Device Regulators Forum
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letter
 
Development and Regulatory Approval of Biologics in European Union (Investiga...
Development and Regulatory Approval of Biologics in European Union (Investiga...Development and Regulatory Approval of Biologics in European Union (Investiga...
Development and Regulatory Approval of Biologics in European Union (Investiga...
 
Ghtf study group 4
Ghtf study group 4Ghtf study group 4
Ghtf study group 4
 
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxGLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
 
GMP for Nutraceuticals .pdf
GMP for Nutraceuticals  .pdfGMP for Nutraceuticals  .pdf
GMP for Nutraceuticals .pdf
 
Cfr 21 part 312
Cfr 21 part 312 Cfr 21 part 312
Cfr 21 part 312
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
 

Semelhante a Regulatory guidelines for the development of biologics in

Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaTGA Australia
 
ich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxJyotshnaDevi4
 
Scope of pharmacology
Scope of pharmacologyScope of pharmacology
Scope of pharmacologyjireankita
 
Drug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuDrug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuTammiraju Iragavarapu
 
Introduction to drug discovery and development.pptx
Introduction to drug discovery and development.pptxIntroduction to drug discovery and development.pptx
Introduction to drug discovery and development.pptxMingmaLhamuBhutia
 
PreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfPreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfsayedjannatfatema72
 
Regulatory framework for new drug development
Regulatory framework for new drug developmentRegulatory framework for new drug development
Regulatory framework for new drug developmentDr. Mohit Kulmi
 
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.comDrug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.comNeelima Sharma
 
Drug development process and clinical trial for UGs
Drug development process and clinical trial for UGsDrug development process and clinical trial for UGs
Drug development process and clinical trial for UGsSameerKhasbage
 
Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Jobin Kunjumon Vilapurathuu
 
Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
 
Lecture 4 Ethic (1).pptx
Lecture 4 Ethic  (1).pptxLecture 4 Ethic  (1).pptx
Lecture 4 Ethic (1).pptxamalhw
 

Semelhante a Regulatory guidelines for the development of biologics in (20)

CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
 
Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in Australia
 
ich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptx
 
Scope of pharmacology
Scope of pharmacologyScope of pharmacology
Scope of pharmacology
 
Drug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuDrug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi raju
 
Introduction to drug discovery and development.pptx
Introduction to drug discovery and development.pptxIntroduction to drug discovery and development.pptx
Introduction to drug discovery and development.pptx
 
PreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdfPreClinical Development_Final_clinical.pdf
PreClinical Development_Final_clinical.pdf
 
Regulatory framework for new drug development
Regulatory framework for new drug developmentRegulatory framework for new drug development
Regulatory framework for new drug development
 
Molecule to medicine
Molecule to medicineMolecule to medicine
Molecule to medicine
 
Clinical research protocol
Clinical research protocolClinical research protocol
Clinical research protocol
 
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.comDrug discovery By  Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
Drug discovery By Neelima Sharma WCC chennai,neelima.sharma60@gmail.com
 
Clinical Trial Primer
Clinical Trial PrimerClinical Trial Primer
Clinical Trial Primer
 
Icmr Code
Icmr CodeIcmr Code
Icmr Code
 
Drug development process and clinical trial for UGs
Drug development process and clinical trial for UGsDrug development process and clinical trial for UGs
Drug development process and clinical trial for UGs
 
Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........
 
Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology
 
Ich guidlines
Ich guidlinesIch guidlines
Ich guidlines
 
Lecture 4 Ethic (1).pptx
Lecture 4 Ethic  (1).pptxLecture 4 Ethic  (1).pptx
Lecture 4 Ethic (1).pptx
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
New Drug Discovery.pptx
New Drug Discovery.pptxNew Drug Discovery.pptx
New Drug Discovery.pptx
 

Mais de JAYA PRAKASH VELUCHURI

Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptxBasics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptxJAYA PRAKASH VELUCHURI
 
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSUREHUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSUREJAYA PRAKASH VELUCHURI
 
FIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIAFIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIAJAYA PRAKASH VELUCHURI
 
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA JAYA PRAKASH VELUCHURI
 
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...JAYA PRAKASH VELUCHURI
 
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONSIMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONSJAYA PRAKASH VELUCHURI
 
Registration requirments for cis countries
Registration requirments for cis countriesRegistration requirments for cis countries
Registration requirments for cis countriesJAYA PRAKASH VELUCHURI
 
Documentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodiumDocumentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodiumJAYA PRAKASH VELUCHURI
 

Mais de JAYA PRAKASH VELUCHURI (17)

Tangential Flow Filtration - PPT.pptx
Tangential Flow Filtration - PPT.pptxTangential Flow Filtration - PPT.pptx
Tangential Flow Filtration - PPT.pptx
 
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptxBasics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
Basics of Biologics| Biosimilars| USFDA| In View of Regulatory Point.pptx
 
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSUREHUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
HUMAN CHALLENGE STUDIES TO ACCELERATE CORONA VIRUS VACCINE LICENSURE
 
FIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIAFIXED DOSE COMBINATIONS BANNED IN INDIA
FIXED DOSE COMBINATIONS BANNED IN INDIA
 
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
AN OVERVIEW ON FIXED DOSE COMBINATIONS AND ITS REGULATIONS IN INDIA
 
HOMEOPATHY IN INDIA AND US OVERVIEW
HOMEOPATHY IN INDIA AND US OVERVIEWHOMEOPATHY IN INDIA AND US OVERVIEW
HOMEOPATHY IN INDIA AND US OVERVIEW
 
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
 
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONSIMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
IMPACT OF REGULATIONS ON MEDICAL DEVICES IN CONTEXT OF INNOVATIONS
 
CASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROLCASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROL
 
Registration requirments for cis countries
Registration requirments for cis countriesRegistration requirments for cis countries
Registration requirments for cis countries
 
Documentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodiumDocumentation of raw material analysis for croscarmellose sodium
Documentation of raw material analysis for croscarmellose sodium
 
Response to a warning letter
Response to a warning letterResponse to a warning letter
Response to a warning letter
 
Ge health care and mri
Ge health care and mriGe health care and mri
Ge health care and mri
 
ICH AND ICH GUIDELINES
ICH AND ICH GUIDELINESICH AND ICH GUIDELINES
ICH AND ICH GUIDELINES
 
Mutual recognition
Mutual recognitionMutual recognition
Mutual recognition
 
THIN LAYER CHROMATOGRAPHY
THIN LAYER CHROMATOGRAPHYTHIN LAYER CHROMATOGRAPHY
THIN LAYER CHROMATOGRAPHY
 
Gamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash raGamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash ra
 

Último

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 

Último (20)

Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 

Regulatory guidelines for the development of biologics in

  • 1. Regulatory Guidelines for the Development of Biologics in the Europe JAYA PRAKASH V, REGULATORY AFFAIRS, 218311.
  • 2. CONTENTS • Introduction • EU Guidelines Non clinical studies Clinical studies MAA • Regulatory strategy for marketing
  • 3. INTRODUCTION • In the European Union, biologics are largely defined in terms of their active substances and methods of manufacture. • EU recognize that biologics are comes under special treatment. • This document provides an overview of the EU regulatory schemes, from nonclinical trials through clinical trials to approval.
  • 4. EUROPEAN UNION GUIDELINES • Biological medicines are defined as “products, the active substance of which is a biological substance. • A “biological substance” in turn, is defined as “a substance that is produced by or extracted from a biological source. • And needs for its characterization and the determination of its quality ,physico-chemical-biological testing, together with the production process and its control.
  • 5. Examples • Immunologic medicines. • Medicines derived from human blood and plasma. • Medicines developed by means of recombinant DNA technology. • Hybridoma and mAb methods.
  • 6. Nonclinical Studies • The Committee for Medicinal Products for Human Use (CHMP) has adopted ICH S6 as a guideline governing preclinical testing of biologics. • The CHMP adopted the addendum to this guideline, and the addendum came into effect in Europe in 2011. • The addendum complements, clarifies, and updates ICH S6 and is intended to further harmonize the standards for nonclinical studies.
  • 7. General Principles The addendum covers the following five topics: Species selection Study design Immunogenicity Reproductive and developmental toxicity Carcinogenicity
  • 8. Species Selection • According to the addendum the factors that sponsors should consider are as follows: subsequent in vitro assays making qualitative and quantitative cross species comparisons of relative target binding affinities. receptor– ligand occupancy. kinetics. Sponsors also should assess functional activity.
  • 9. • Specific instructions are provided for mAbs, for which a short term safety study in one species and no additional toxicity studies are recommended. • If there are two relevant species (one rodent and one non rodent), the sponsor should conduct short-term studies in both. • If the toxicologic findings from these studies are similar for both species, long-term studies may involve one of those species.
  • 10. Study Design • When selecting the high dose for toxicity testing , the high dose should be the higher of - The dose providing the maximum intended pharmacologic effect in the preclinical species. The dose providing an approximately 10-fold exposure over the maximum exposure to be achieved in the clinic. When no PD endpoint is available, the sponsor should select the high dose based on PK data.
  • 11. • Generally, repeat-dose toxicity tests should have a duration of 6 months; studies of longer duration are not considered valuable. • Finally, the sponsor may need to assess subject recovery from the medicine’s pharmacologic and toxicologic effects.
  • 12. Immunogenicity • As noted in ICH S6,non clinical studies are not useful in predicting potential immunogenicity of human or humanized proteins in humans. • The sponsor should measure antidrug antibodies (ADAs), namely when (1) There is evidence of altered PD activity. (2) There are unexpected changes in exposure in the absence of a PD marker. (3) there is evidence of immune-mediated reactions. • Collection of appropriate samples during the study is recommended.
  • 13. Reproductive and Developmental Toxicity • The addendum first provides general advice on reproductive and developmental testing and then discusses more specific recommendations for Fertility studies. Embryo–fetal development (EFD) studies. pre-and post natal development (PPND)studies. Studies in nonhuman primates (NHPs).
  • 14. • Reproductive studies should occur in a relevant species, but no such studies are required for products directed at foreign targets, such as bacteria and viruses. • Sponsors should not use NHPs in developmental testing unless they are the only relevant species, and even then, the sponsor can provide scientific justification to use an alternative model.
  • 15. • If no relevant species exists, the sponsor may consider using transgenic mice. • If the weight of the evidence suggests an adverse effect on fertility or pregnancy, and additional studies might not be warranted.
  • 16. • When the product’s mechanism of action raises serious developmental toxicity concerns and NHPs are the only relevant species. • No study is necessary. instead, the labeling should disclose the concern, and the sponsor should avoid administering the candidate to women of child bearing potential
  • 17. Carcinogenicity • As noted, carcinogenicity assessments of biologics are not always warranted, but the addendum provides advice for use in situations when they are appropriate. • According to the addendum, the sponsor may design a strategy addressing potential carcinogenicity based on a weight of evidence, including a review of relevant information such as : • Literature. • Target biology and mechanisms of action. • In vitro data . • Clinical data. • Data from chronic toxicity studies.
  • 18. • In situations the weight of the evidence supports them, the hazard should be addressed through product labeling and risk management practices. • If the weight of the evidence is unclear, the sponsor can propose additional studies to address it. • If this assessment instead suggests no carcinogenicity concern, additional nonclinical testing is not recommended.
  • 19. Clinical Studies in Compliance with the Clinical Trials Directive • This section summarizes the requirements of the Clinical Trials Directive. Clinical trail authorisation Good clinical practice and other aspects Study design Consultation with EMA CLININCAL TRAILS REQUIRMENTS
  • 20. Clinical Trial Authorization A clinical trial may commence only if :  The anticipated therapeutic and public health benefits outweigh risks and inconveniences to the subjects.  The trial subjects understand the objectives and risks of the trial and give informed, written consent to participate.  The trial safeguards the physical and mental integrity of the subjects.  Insurance covers the liability of the sponsor and investigator.
  • 21. • In general, the sponsor must take responsibility for the following: Trial conduct Appointment of an appropriate investigator selection of the institution that will conduct the trial data collection standards etc., • The trial may begin only if (1) The ethics committee has issued a favorable opinion. (2) No competent authority has informed the applicant of grounds for non acceptance.
  • 22. Good Clinical Practices and Other aspects for Clinical Trials • Clinical trials of biologics must comply with Good Clinical Practice and the ICH E6. • Investigators must obtain freely given informed consent. • Clinical trial information must be handled, recorded, and stored with respect for relevant confidentiality and privacy rules. • Trials must comply with the ethical principles. • Confirm that the benefits of the trial outweigh the risks, and ensure safety to the subjects.
  • 23. • CHMP has issued a guideline on quality : An adequate description of the process and process controls. A description and justification of “any reprocessing during manufacture of the drug substance”. • For first-in-human (FIH) clinical trials, sponsors should use product representative of the material used during the nonclinical testing phase.
  • 24. Study Design Considerations • General guidance on study design applies to biologics as well as small molecule medicines. • Phase I usually involves the initial safety and pk studies. • phase II study is a therapeutic exploratory study that explores efficacy. • Phase III typically involves therapeutic confirmatory studies.
  • 25. Consultation with the EMA • A sponsor may obtain, from the EMA, scientific advice regarding clinical trial protocols. • Generally focus on matters such as the selection of endpoints and comparator, the duration of treatment or follow-up, and the design of pivotal studies. • If the applicant decides not to follow the EMA’s advice, it should justify this decision in its MAA.
  • 26. The Marketing Authorization Application- Contents and Approval Standard The requirements of the EU centralized procedure are : The approval standards for Biotechnology products are the same as for chemically synthesized medicines. Both types of products must be safe and effective and have appropriate quality. MAAs for biologics also must meet special requirements: The applicant must thoroughly describe the manufacturing process , facilities and equipment. provide information on the origin and history of the starting materials.
  • 27. demonstrate that the active substance complies with specific measures for preventing the transmission of animal spongi form encephalopathies. if cell banks are used, demonstrate that cell characteristics remain unchanged at the passage level for production (and beyond). describe the origin, criteria, and procedures for the collection, transportation, and storage of the starting material if they derived from human blood and plasma
  • 28. REGULATORY STRATEGIES FOR WORLDWIDE MARKETING OF BIOLOGICAL PRODUCTS • Acceptance of Foreign Clinical Studies in the Europe • Europe Directive 2001/83/EC allows for clinical trials conducted outside the European Union. • If such trials have been designed, implemented, and reported based on principles equivalent to those of the Clinical Trials Directive with regard to good clinical practice and ethical principles.
  • 29. Success is never owned; it is only rented, and the rent is due every day! THANK YOU